## Clinical Context This patient presents with **acute decompensated heart failure (ADHF)** superimposed on chronic systolic heart failure. He has signs of volume overload (orthopnea, edema, elevated JVP, pulmonary edema on imaging) and is on triple therapy but inadequately controlled. ## Rationale for Correct Answer **Key Point:** In acute decompensated systolic heart failure with volume overload, the immediate priority is: 1. **Diuresis** — IV furosemide to relieve congestion 2. **Optimization of guideline-directed medical therapy (GDMT)** — ensure adequate doses of ACE-I/ARB and beta-blocker 3. **Addition of ARNI** — sacubitril/valsartan is superior to ACE inhibitors alone in systolic HF and should be introduced once acute decompensation is stabilized **High-Yield:** ARNI (sacubitril/valsartan) reduces mortality and hospitalization more than ACE inhibitors in HFrEF [cite:Harrison 21e Ch 297]. It is typically initiated after acute symptoms are controlled and renal function/potassium are stable. **Clinical Pearl:** The patient is not in cardiogenic shock (BP adequate, no hypoperfusion signs), so inotropes are not indicated. His LVEF is reduced but not so severe as to mandate immediate transplant listing without optimization of medical therapy first. ## Why This Approach Works ```mermaid flowchart TD A[Acute Decompensated HFrEF<br/>with Pulmonary Edema]:::outcome --> B{Hemodynamically<br/>Stable?}:::decision B -->|Yes| C[IV Diuretics<br/>Optimize ACE-I/BB]:::action B -->|No| D[Inotropes ±<br/>Vasopressors]:::urgent C --> E[Stabilization<br/>Achieved?]:::decision E -->|Yes| F[Add ARNI<br/>Consider ICD/CRT<br/>if EF ≤35%]:::action E -->|No| G[Escalate to<br/>Advanced Therapies]:::urgent F --> H[Outpatient Follow-up<br/>1–2 weeks]:::action ``` ## Key Management Principles | Step | Timing | Rationale | |------|--------|----------| | IV Furosemide | Immediate | Relieve pulmonary congestion, reduce preload | | Optimize ACE-I/BB | During hospitalization | Ensure target or near-target doses | | Add ARNI | After acute stabilization | Superior to ACE-I alone; requires stable renal function and K⁺ | | Assess for ICD/CRT | Before discharge | LVEF ≤35% warrants device evaluation | | Outpatient cardiology | Within 1–2 weeks | Monitor response, titrate therapy | **Mnemonic: ADOPT** — **A**cute diuresis, **D**rug optimization, **O**ptimize with ARNI, **P**erfusion assessment, **T**ransplant/device evaluation if needed. ## Why Inotropes Are Not First-Line Here Inotropes (dobutamine, milrinone) are reserved for: - Cardiogenic shock with hypotension or end-organ hypoperfusion - Acute decompensation *despite* diuretics and vasopressors This patient has adequate blood pressure and no shock physiology, so inotropes would be premature and increase mortality risk.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.